Butterfly Network, Inc. Class A (BFLY)

In the past six months, Butterfly Network's stock price has been impacted by several events. On February 26, 2026, the stock price increased significantly by +50.65% following the report of Fourth Quarter 2025 Financial Results. On March 10, 2026, Butterfly Network announced the appointment of David Horsley as Senior Vice President, Innovation – Butterfly Embedded™. On March 30, 2026, the company secured its first FDA clearance for a Blind Sweep Ultrasound AI Tool, aimed at women's health. On April 10, 2026, the stock experienced a drop of 0.72% compared to its opening price. Over the last 12 months, the stock price has increased by 102.70%, with a year-to-date return of 8.82%.

Analysis of Butterfly Network, Inc.'s seasonal charts suggests a period of seasonal strength for the Healthcare sector from April 25 to December 4. For BFLY specifically, a "Buy Date" of May 13 and a "Sell Date" of August 4 has historically resulted in a geometric average return of 6.88% above the S&P 500 Total Return Index over the past 5 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 out of 5 periods. However, it is important to note that only 5 years of data are available for BFLY, which may be insufficient to create a fully reliable seasonal profile.

Butterfly Network, Inc. is a digital health and healthcare company focused on transforming medical imaging through portable, semiconductor-based ultrasound technology and software solutions. The company's core technology is its Ultrasound-on-Chip, which enables handheld, whole-body ultrasound imaging combined with cloud-connected, software-driven workflows. Key products include the Butterfly iQ family of devices (iQ+, iQ3), Butterfly Move, iQ+ Bladder, Compass enterprise workflow software, Compass AI, ScanLab, and Butterfly iQ+/iQ3 Vet. The company's business model combines device revenue with recurring software subscriptions, educational tools, AI modules, and enterprise services.

Butterfly Network, Inc. develops, manufactures, and commercializes its ultrasound imaging solutions in the United States and internationally. Its corporate headquarters are located in Burlington, Massachusetts, with other offices in Guilford, Connecticut, New York City, and Palo Alto. The Butterfly iQ+ can be purchased by healthcare practitioners in numerous countries, including the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom. The company also emphasizes initiatives in global health, particularly in low- and middle-income countries, to expand access to ultrasound.

In the past year, Butterfly Network has received positive recognition for its innovations, including the iQ3 device being recognized with the Best Medical Technology award at the Prix Galien USA Awards. The company's innovations have also been featured on lists such as Fierce 50, TIME's Best Inventions, and Fast Company's World Changing Ideas. In late 2024, Octiv was formed as a wholly-owned subsidiary with an exclusive license to all Butterfly IP. In March 2025, William Blair initiated research coverage with a positive outlook.

Butterfly Network, Inc. has a mixed ownership structure, with institutional shareholders, individual insiders, and retail investors. As of April 10, 2026, there are 209 institutional owners and shareholders holding a total of 119,166,435 shares. Major institutional owners include BlackRock, Inc., Glenview Capital Management, Llc, Vanguard Group Inc, Fosun International Ltd, Hood River Capital Management LLC, ARK Investment Management LLC, State Street Corp, Geode Capital Management, Llc, AWM Investment Company, Inc., and Millennium Management Llc. Significant individual owners include Jonathan M. Rothberg, 4c Holdings I LLC, Larry Robbins, and Joseph Devivo.